Invivyd Announces Positive Phase 1/2 Data for VYD2311 for COVID-19
Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, a monoclonal antibody designed to offer superior, long-lasting protection...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, a monoclonal antibody designed to offer superior, long-lasting protection...
Median Technologies announced positive top-line results from its RELIVE study for eyonis™ LCS, an AI-powered lung cancer screening software....
Researchers found that C2N Diagnostics‘ PrecivityAD2 blood test improved healthcare providers’ ability to assess the likelihood of Alzheimer’s diseaseAlzheimer’s...
Eli Lilly’s Omvoh, an IL-23 inhibitor previously approved for ulcerative colitis, has received FDA approval for Crohn’sCrohn’s disease. Despite...
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has been recommended for approval...
CervoMed provided an update on its Phase 2b RewinD-LB trial for neflamapimod in dementia with Lewy bodies (DLB). The...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Merck’s CAPVAXIVE, a 21-valent...
Eisai and Biogen provided an update on the European Union’s regulatory review of lecanemab, a treatment for early-stage Alzheimer’s...
Rapid Medical has enrolled the first patient in its COGNITIVE study, investigating the link between mechanical thrombectomy using their...
New data from the Tufts Center for the Study of Drug Development (CSDD) reveals a correlation between decentralized clinical...